Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Open-label Study of Etrasimod in IBD Patients With Active Skin Extra-intestinal Manifestations
2016-003797-40Phase 2Completed
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etrasimod in inflammatory bowel disease (IBD) and Extraintestinal manifestation of inflammatory bowel disease (EIM), sponsored by Arena Pharmaceuticals, Inc. Primary endpoint: Exploratory efficacy and safety endpoints. Started Oct 2016; status: completed.
02
Drugs
etrasimod
03
Conditions
inflammatory bowel disease (IBD)Extraintestinal manifestation of inflammatory bowel disease (EIM)
Beyond the preview
Go deeper on 2016-003797-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003797-40.